Longevity & Aging
GLP-1 Drugs Like Semaglutide Quietly Deplete Key Nutrients Over Time
A review of 480,000+ adults finds GLP-1 receptor agonist users face rising deficits in vitamin D, iron, calcium, and B vitamins.
Research Paper
Jun 22, 2026 0
Results for "Tirzepatide Longevity" in Parkinson's
50 articles
Regenerative Medicine
Biomimetic Hematoma Scaffold Heals Stubborn Bone Fracture in 80-Year-Old
A novel bone-mimicking scaffold delivering low-dose rhBMP-2 achieved complete fracture union in 4 months in a medically complex elderly patient.
Research Paper
Jun 22, 2026 0
Metabolic Health
Precision Obesity Medicine Maps Best Drugs to Patient Phenotype and Age
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
Research Paper
Jun 22, 2026 0
Nutrition & Diet
Beyond Ozempic: How Combining GLP-1 Drugs with Surgery Could Redefine Obesity Treatment
Experts say the next era of obesity care pairs GLP-1 medications with precision medicine, endoscopic procedures, and surgery for lasting results.
Press Release
Jun 21, 2026 0
Hormones
Obesity Drugs May Boost Testosterone and Improve Sperm Quality in Men
GLP-1 receptor agonists used for obesity may deliver an unexpected reproductive benefit: higher testosterone and better sperm.
Research Paper
Jun 20, 2026 0
Longevity & Aging
Semaglutide Linked to 15% Lower Fracture Risk in Type 2 Diabetes Patients
A large records review finds semaglutide users had significantly fewer bone fractures than those on other diabetes or weight-loss drugs.
Press Release
Jun 16, 2026 0
Hormones
Obesity Drugs Found to Boost Testosterone and Sperm Quality in Men
GLP-1 receptor agonists used for weight loss may also restore male reproductive hormones and improve sperm parameters.
Research Paper
Jun 16, 2026 0
Longevity & Aging
New Drug Combo Boosts Tirzepatide Weight Loss by 4.5% While Targeting Brain and Muscle Health
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
Press Release
Jun 13, 2026 0
Longevity & Aging
New Drug MS-001 Boosts GLP-1 Weight Loss and Prevents Rebound in Animal Tests
Preclinical data shows MS-001 deepens weight loss with semaglutide, preserves muscle, and curbs regain after stopping GLP-1 drugs.
Press Release
Jun 12, 2026 0
Longevity & Aging
GLP-1 Drugs Cut Obesity-Related Cancer Risk by 41% in Landmark Study
A large cohort study finds GLP-1 receptor agonists slash obesity-linked cancer risk by 41%, with tirzepatide outperforming semaglutide dramatically.
Press Release
Jun 9, 2026 0
Longevity & Aging
New Drug Combo Adds 4.5% More Weight Loss on Top of Tirzepatide in Trial
OrsoBio's oral TLC-6740 paired with tirzepatide boosted weight loss by an extra 4.5% in 24 weeks, with gains in insulin sensitivity and liver health.
Press Release
Jun 9, 2026 0
Longevity & Aging
New Obesity Drug Ribupatide Achieves 12% Weight Loss in Phase 2 Oral Trial
A once-daily pill and weekly injection show promising weight loss results, rivaling existing GLP-1 therapies in early clinical testing.
Press Release
Jun 9, 2026 0
Page 1 of 5Next